177276-39-0

Usage

Molecular structure

A compound derived from piperidine, a heterocyclic amine, with additional functional groups.

Functional groups

Contains a carboxylic acid group (-COOH) and an ester group (-COO-).

Substitution pattern

The ester group is a 1,1-dimethylethyl ester, and the piperazine ring is substituted with a phenylmethyl group at the 4-position.

Use in pharmaceutical industry

Commonly employed as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients.

Potential applications

Utilized in the treatment of neurological and psychiatric disorders, as well as in the development of novel therapeutic agents.

Unique chemical structure

The compound has a distinct chemical structure that contributes to its pharmacological properties.

Pharmacological properties

Of interest to researchers and pharmaceutical companies for its potential in drug discovery and development.

Upstream product

• 2759-28-6 1-phenylmethylpiperazine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 177276-41-4 4-(piperazin-1-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 686298-00-0 1-benzyl-4-piperidin-4-yl-piperazine 

Relevant academic research and scientific papers

Puerarin derivative and its preparation method (by machine translation)

The invention belongs to the technical field of organic synthetic chemistry, and provides a plurality of puerarin derivatives and preparation methods thereof. The prepared puerarin derivatives have good water solubility or fat solubility, and can be quick

5-Quinoline derivatives having an anti-bacterial activity

The present invention describes novel anti-bacterial compounds of the formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase and topoisomerases, for example of topoisomerase II and IV.

Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain

The present invention concerns novel benzenesulphonamide compounds, defined by formula I and the description, their method of preparation and their use in therapy.

SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT

The invention relates to CGRP antagonists of general formula (I), in which A, U, V, W, X and R1 to R 3 are as defined in claim 1, the tautomers, diastereomers, enantiomers, hydrates, mixtures, salts, hydrates of the salts, in particular the physiologically-acceptable salts thereof with inorganic or organic acids, medicaments containing said compounds and the use and methods for production thereof.

Modified aminoacids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4and R11are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Compounds with platelet aggregation inhibitor activity

A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the aggregation of platelets is disclosed: STR1 wherein A, B and C represent independently CH2 or C=O;